^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TQB2618

    i
    Other names: TQB2618
    Associations

    News

    Trials
    Company:
    Sino Biopharm
    Drug class:
    TIM-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    TQB2618-AK105-Ib-04: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). (clinicaltrials.gov)
    P1, N=29, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jun 2025; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns
    Trial termination • Trial primary completion date
    |
    Focus V (anlotinib) • Anniko (penpulimab) • TQB2618
    5ms
    TQB2618-AK105-Ib-03: Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=34, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=75 --> 34 | Trial completion date: Dec 2024 --> Mar 2025 | Recruiting --> Terminated; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • Anniko (penpulimab) • TQB2618
    1year
    TQB2618-AK105-Ib-03: Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=75, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Dec 2024
    Enrollment open • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • Anniko (penpulimab) • TQB2618
    almost2years
    A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. (clinicaltrials.gov)
    P1, N=75, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024
    Enrollment open • Trial initiation date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Focus V (anlotinib) • Anniko (penpulimab) • TQB2618
    over2years
    A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. (clinicaltrials.gov)
    P1, N=75, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Focus V (anlotinib) • Anniko (penpulimab) • TQB2618
    over2years
    Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma (clinicaltrials.gov)
    P1, N=50, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • TQB2618
    over2years
    Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=75, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • Anniko (penpulimab) • TQB2618
    almost3years
    Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=127, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    PD-L1 expression • ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation
    |
    Andewei (benmelstobart) • TQB2618
    3years
    TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=110, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • gemcitabine • Anniko (penpulimab) • TQB2618
    over3years
    To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Pembrolizumab in the Treatment of Patients With Relapsed and Refractory Lymphoma (clinicaltrials.gov)
    P1/2, N=92, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Keytruda (pembrolizumab) • Anniko (penpulimab) • TQB2618